Author

L. M. Jeworowski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

C. Drosten· 4 shared V. M. Corman· 4 shared M. L. Schmidt· 3 shared A. C. Hocke· 2 shared A. Richter· 2 shared D. Schmitz· 2 shared E. Sanchez-Sendin· 2 shared H.-C. Kornau· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

C. Drosten

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ImmunologySciencePeer-reviewedOct 6, 2023

Mapping SARS-CoV-2 antigenic relationships and serological responses

S. H. Wilks, B. Muhlemann, X. Shen…·D. J. Smith

The paper uses antigenic cartography to analyze cross-reactivity among SARS-CoV-2 variants and human sera, identifying amino acid substitutions and immunodominance patterns affecting immune escape and vaccine efficacy.

DOI 10.1126/science.adj0070

humanproteomics

𝕏 PostBluesky

MicrobiologybioRxivPreprintOct 20, 2021

Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line

D. Niemeyer, S. Schroeder, K. Friedmann…·C. Drosten

The paper shows that B.1.1.7 and B.1.617.2 SARS-CoV-2 variants have a replication advantage over B.1 in ACE2-deficient lung cells, suggesting reliance on alternative cellular factors.

DOI 10.1101/2021.10.20.465121

humanexperimental assay

𝕏 PostBluesky

ImmunologybioRxivSep 30, 2021

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

S. M. Reincke, M. Yuan, H.-C. Kornau…·J. Kreye

SARS-CoV-2 Beta variant infection generates lineage-specific antibodies and cross-reactive antibodies with neutralizing activity against wild-type and other variants.

DOI 10.1126/science.abm5835

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivAug 15, 2020

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

J. Kreye, S. M. Reincke, H.-C. Kornau…·N. Osterrieder

This study identifies a potent SARS-CoV-2 neutralizing antibody that protects hamsters from infection and lung damage.

DOI 10.1016/j.cell.2020.09.049

mouseproteomics

𝕏 PostBluesky